TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed small cell lung cancer, meeting 1 of the following criteria:~  * Previously untreated metastatic or extensive disease~    * Malignant pleural effusion or multifocal lung disease is considered metastatic or extensive disease~   * Prior radiotherapy allowed~ * Recurrent disease~    * Limited, metastatic, or extensive disease~   * Relapsed after prior chemotherapy, excluding irinotecan hydrochloride~      * At least 90 days since prior chemotherapy~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 1 cm by physical examination or radiographic techniques~* Known brain metastases allowed~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* White Blood Cells \> 3,000/mm³~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 9.0 g/dL~* Bilirubin ≤ 1.5 mg/dL~* SGOT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* No medical disease that, in the opinion of the investigator, would preclude study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 10 days since prior radiotherapy (including brain)~* No prior irinotecan hydrochloride~* At least 2 weeks since prior and no concurrent anticonvulsants~* No concurrent radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metastatic SCLC (Type: EXPERIMENTAL): Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
- Relapsed SCLC (Type: EXPERIMENTAL): Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intubated, on mechanical ventilation, and anticipated to remain on mechanical ventilation for 2 days after enrollment into the study~* Receiving enteral feeding and assessed to have developed EFI, as defined by a GRV measurement ≥250 mL within the 24 hours before randomization~Exclusion Criteria:~* History of diabetic or idiopathic gastroparesis~* Screening blood glucose \>15 mmol/L (270 mg/dL) while receiving insulin~* Impaired renal function, as defined by estimated glomerular filtration rate (eGFR) \<30 mL/min, as determined by the Cockcroft-Gault formula -Bilirubin concentration in blood \>2 times the upper limit of normal~* ALT or AST \>3 times upper limit of normal~* Alkaline phosphatase \>2 times upper limit of normal~* Contraindication to enteral feeding~* Opioid or other drug overdose as the primary reason for admission to Intensive Care Unit (ICU)~* Receipt of a drug that can be used as a gastric prokinetic agent~* Receipt of agents known to directly influence the 5 HT4/acetylcholine prokinetic mechanism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- TD-8954 (Type: EXPERIMENTAL): TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours
- Metoclopramide (Type: ACTIVE_COMPARATOR): Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria (main):~* \> 4 watery/soft stools on at least 4 days in the week prior to baseline~* \> 3 stools per day on average within the last 7 days prior to baseline~* Symptoms (chronic watery diarrhea) for at least 3 months before baseline~* Complete colonoscopy within the last 12 weeks before baseline~* Histologically confirmed diagnosis of collagenous colitis~Exclusion Criteria:~* Evidence of infectious diarrhea~* Celiac disease~* Endoscopic-histologic findings, which may have caused diarrhea~* History of partial colonic resection~* Diarrhea as a result of the presence of other symptomatic organic disease of the gastrointestinal tract~* Active colorectal cancer or a history of colorectal cancer~* Severe co-morbidity substantially reducing life expectancy~* Abnormal hepatic function or liver cirrhosis (ALT, AST or AP \>= 2 x ULN)~* Abnormal renal function (Cystatin C \> ULN)~* Active peptic ulcer disease, local intestinal infection~* Asthma, diabetes mellitus, infection, osteoporosis, glaucoma, cataract, or cardiovascular disease if careful medical monitoring is not ensured~* Hemorrhagic diathesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of parent clinical trial for treatment of partial seizures~Exclusion Criteria:~* Receiving any study drug or experimental device other than lacosamide~* Meets withdrawal criteria for parent trial or experiencing ongoing serious adverse event

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Up to 800 mg/day lacosamide (flexible dosing)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patients with primary immunodeficiency~* Patients who have received stable IVIG therapy at 3- or 4-weekly intervals for at least 6 months~Key Exclusion Criteria:~* Newly diagnosed PID~* Allergic reactions to immunoglobulins or other blood products~* Administration of steroids (daily ≥ 0.15 mg prednisone equivalent/kg/day) or other immunosuppressive drugs~* Concomitant diseases such as hypoalbuminemia, protein-losing enteropathies, kidney diseases with proteinuria, malignancies of lymphoid cells (e.g. lymphocytic leukemia), and recent history of migraine~* History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, severe hypertension

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IgPro10 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis in Peri-implant Mucositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* completely edentulous lower or upper dental arch undergoing rehabilitation with dental implants;~* prosthetic restoration in function for at least 6 months;~* healthy individuals with no known systemic changes;~* non smokers.~Exclusion Criteria:~* patients who have received any type of local or systemic oral cavity decontamination treatment within the last 3 months or periodontal treatment within the last 6 months; uncontrolled periodontal disease;~* patients with systemic disorders capable of influencing treatment outcomes;~* smokers;~* lack of informed consent to participate in the study;~* presence of bone loss greater than 2 mm in dental implants.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test Group (Type: EXPERIMENTAL): Mechanical treatment + Bifidobacterium animalis subsp. lactis
- Control Group (Type: PLACEBO_COMPARATOR): Mechanical treatment + Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Copper Histidine Therapy for Menkes Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Newborn infants in whom Menkes disease is confirmed on biochemical or molecular grounds and in whom no neurological symptoms are present are eligible for enrollment in this study.~EXCLUSION CRITERIA:~Newly identified patients classified as symptomatic at the time of diagnosis, and affected individuals with mild phenotypes are not currently eligible for this clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copper histidine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methadone in Ambulatory Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* Undergoing general anesthesia and moderately painful, ambulatory surgical procedures with anticipated overnight, postop hospital stay of \< 24 hours~* Signed, written, informed consent~Exclusion Criteria:~* History of or known liver or kidney disease.~* Females who are pregnant or nursing.~* Opioid tolerant patients (e.g. preoperative methadone therapy or use of fentanyl transdermal patches)~* History of allergy to methadone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Control (Intra-operative administration of opioids, other than methadone)
- Treatment methadone 0.1 mg/kg (Type: ACTIVE_COMPARATOR): methadone 0.1 mg/kg
- Treatment methadone 0.15 mg/kg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* 3 months of age and older~* Confirmed diagnosis of atopic dermatitis according to Hanifin and Rajka criteria~* Minimum of 5% BSA affected by atopic dermatitis~* ISGA score of Mild (2) or Moderate (3)~Exclusion Criteria:~- Has any clinically significant medical disorder, condition, or disease (including active or potentially recurrent non AD dermatological conditions and known genetic dermatological conditions that overlap with AD, such as Netherton syndrome).

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crisaborole 2% (Type: EXPERIMENTAL): Crisaborole 2% ointment applied once daily (QD)
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle ointment applied once daily (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Successfully completed Protocol PB-06-001 and enrolled in Protocol PB-06-003~* The subject signs an informed consent~Exclusion Criteria:~* Currently taking another investigational drug for any condition.~* Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Taliglucerase alfa 30 units/kg (Type: EXPERIMENTAL): Subjects randomized to receive 30 units/kg
- Taliglucerase alfa 60 units/kg (Type: EXPERIMENTAL): Subjects randomized to 60 units/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thoracic Paravertebral Block Using Ropivacaine and Dexmedetomidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II grade~* Undergoing elective video-assisted pneumonectomy under general anesthesia.~* Participants aged from 30-70 years old.~Exclusion Criteria:~* Refusal for paravertebral block~* Inability to obtain informed consent~* Coagulation disorders, neuropathy, or body mass index greater than 40 kg/m2~* Pregnancy~* Infections at the site of injection for the paravertebral block~* Allergy to local anesthetics or alpha-2 adrenergic agonists~* Heart block or bradycardia (heart rate \< 60 beat per minute)~* Clinically significant cardiovascular, pulmonary, renal, or hepatic diseases

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ropivacaine and dexmedetomidine (Type: EXPERIMENTAL): Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
- Ropivacaine only (Type: ACTIVE_COMPARATOR): Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 18 or older~* The CHB patients (both HBeAg-positive and - negative) who have at least 6 months undetectable HBV DNA (serum HBV DNA ≤ 20 IU/mL) after lamivudine plus adefovir combination therapy.~Exclusion Criteria:~* Patients with decompensated liver disease~* Patients with HCV, HDV or HIV~* Patients with HCC~* Serum ALT \> 2x ULN level~* Serum creatinine \> 2.0mg/dL~* Pregnant or lactating women~* Women who have a plan for pregnancy within the three coming years~* Patients who have uncontrolled severe concomitant diseases- severe cardiovascular diseases and other infection~* Those who have no capabilities to understand and sign an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamivudine plus adefovir (Type: ACTIVE_COMPARATOR): Continue lamivudine/adefovir add on treatment (standard treatment)
- Tenofovir (Type: EXPERIMENTAL): Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA~* Squamous cell carcinoma (SCC) of head and neck (SCCHN), including all pharynx, larynx, oral cavity, skin and para-nasal sinus sites. Patients with SCC of unknown primary presenting in the neck clinically compatible with head and neck mucosal primary sites are eligible.~* If prior chemoradiation, radiation, and/or surgery in the potentially curative setting, \> 3 months has elapsed since the end of the potentially curative treatment ended~* If history of other malignancies treated curatively \> 1 year prior to enrollment, no evidence of relapse at the time of enrollment~* If brain metastasis, central nervous system (CNS) imaging documents no evidence of CNS progression at least 30 days following definitive CNS treatment (resection or radiation)~* ≥ 16 years old~* Eastern cooperative oncology group (ECOG) Performance Status \< 3~* Laboratory value requirements at enrollment:~* Absolute neutrophil count \> 1500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin \> 8 g/dL~* Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \< 2.5 x upper limit of normal (ULN) unless liver metastases documented. If so, AST and ALT \< 5 x ULN required.~* Total bilirubin \< 1.5 x ULN, EXCEPT if Gilbert's syndrome is present. If so, total bilirubin \< 2.5 x ULN~* Serum Creatinine \< 1.5 mg/dL OR an estimated creatinine clearance from 24 hour urine collection \> 50 mL/min~* Peripheral neuropathy \< grade 2~* Hearing loss in best ear \< grade 2 per Chang criteria if audiogram performed. Formal audiology is not required in patients with no clinical evidence of hearing loss at baseline.~* Ability to understand and the willingness to sign a written informed consent document.~EXCLUSION CRITERIA~* Prior palliative chemotherapy~* Active infections including HIV (EXCEPTION: HIV-positive patients on HAART with undetectable blood HIV levels, or with history or serological evidence of exposure to Hepatitis B without active infection are eligible)~* Prior grade 3 allergic or infusion reactions to docetaxel, cisplatin or cetuximab (EXCEPTION: a history of infusion reactions that were well-tolerated, at physician's discretion)~* Pregnant and/or lactating

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin + Docetaxel + Cetuximab (Type: EXPERIMENTAL): Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ICD-10 diagnosis of schizophrenia, schizoaffective, bipolar or recurring depressive disorder~* Smoking ≥ 5 cigarettes per day over the past 30 days~* Desire to quit smoking in the next 30 days~* Willing and medically eligible to use Nicotine Replacement Therapy~* Fluent in spoken and written English~* Working email, mailing address, or alternative contact person~* Taking psychiatric medications as prescribed by their provider~* Stable housing~Exclusion Criteria:~* Problematic alcohol or illicit drug use in the last 30 days~* Acute psychotic episode, unsafe to participate in the study, or psychiatrically unstable~* Pregnant, breastfeeding, or having the intention to become pregnant in the next 4 months~* Hearing, comprehension, or visual limitations that preclude study participation~* Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation~* Using non-cigarette forms of tobacco as the primary source of nicotine (e.g. e-cigarettes, chew)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Learn to Quit (Type: EXPERIMENTAL): A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
- NCI QuitGuide (Type: ACTIVE_COMPARATOR): A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete